Galapagos selected for AEX Index
June 09 2016 - 1:34AM
Galapagos NV (Euronext & NASDAQ: GLPG) announces that
Euronext has selected Galapagos NV for inclusion in the
AEX®1 Index on Euronext Amsterdam, effective 20 June 2016.
Galapagos is the first biotechnology company ever to be included in
the AEX Index.
The AEX represents the 25 largest companies traded on Euronext
Amsterdam, subject to meeting Euronext Index Family criteria and
review.
"We are proud that 11 years after our initial public listing on
Euronext, Galapagos is included in the prestigious AEX Index. This
reflects the evolution of Galapagos from a pioneering target
discovery company to an integrated biopharmaceutical powerhouse,"
says Onno van de Stolpe, CEO and Founder.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& Corporate Communications +1 781 460 1784 |
Director
Communications +31 6 53 591 999 communications@glpg.com |
Paul van der Horst Director IR & Business Development +31 6 53
725 199 |
|
ir@glpg.com |
|
Forward-Looking Statements This release may contain
forward-looking statements, including statements. Galapagos
cautions the reader that forward-looking statements are not
guarantees of future performance. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. A further list and description
of these risks, uncertainties and other risks can be found in
Galapagos' Securities and Exchange Commission (SEC) filing and
reports, including in Galapagos' most recent annual report on Form
20-F filed with the SEC and subsequent filings and reports filed by
Galapagos with the SEC. Given these uncertainties, the reader
is advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in
this document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
1AEX® is a registered trademark of Euronext
GLPG selected for AEX Index
http://hugin.info/133350/R/2019173/749549.pdf Galapagos selected
for AEX Index http://hugin.info/133350/R/2019173/749554.pdf
HUG#2019173
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024